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Background: Initial complete resection is a powerful prognostic indi-
cator of survival in thymic epithelial tumors (TETs), but is obviously 
related to tumor stage. Here, we report the results of a prospective 
study of neoadjuvant docetaxel/cisplatin in locally advanced TETs.
Methods: Patients with histologically proven, Masaoka stage III/
IV TETs at presentation were enrolled in this open-label, phase II, 
nonrandomized study. Patients received docetaxel 75 mg/m2 I.V, fol-
lowed by cisplatin 75 mg/m2 I.V on day 1 of every 3-week cycle. 
After three cycles, surgical resection was performed if the tumor was 
considered resectable.
Results: From March 2007 to July 2011, 27 patients were enrolled in 
the trial. Masaoka stage at presentation was III (n = 8; 29.6%), IVA 
(n = 17; 63.0%), and IVB (n = 2; 7.4%). Histologic types were nine 
thymomas (33.3%) and 18 thymic carcinomas (66.7%). After com-
pletion of neoadjuvant chemotherapy, 17 patients (63.0%) achieved 
partial response and 10 (37.0%) had stable disease. Nineteen patients 
(70.4%) underwent surgery and eight did not because of surgeons’ 
decision (n = 5), patient refusal (n = 2), or decision to undergo radia-
tion therapy instead (n = 1). Fifteen among the 19 patients achieved 
complete resection (78.9%), which yields 55.6% of complete resec-
tion rate with intent-to-treat analysis. The most common side effects 
of severity greater than grade 3 were neutropenia and diarrhea. With 
a median follow-up of 42.6 months, 4-year overall survival, and pro-
gression-free survival in all patients was 79.4 and 40.6%, respectively.
Conclusion: Neoadjuvant docetaxel/cisplatin is both feasible and 
well tolerated, and potentially improves surgical resectability in 
patients with advanced TETs.
Key Words: Thymic tumor, Resectability, Preoperative chemother-
apy, Docetaxel/cisplatin.
(J Thorac Oncol. 2013;8: 959-966)
Although thymic epithelial tumors (TETs) are rare human neoplasms, they comprise the majority of thymic lesions, 
accounting for 50% of anterior mediastinal masses in adults.1,2 
TETs include thymoma and thymic carcinoma3,4 and are primar-
ily a surgical disease. Complete surgical resection is the most 
effective treatment modality,4–7 and the majority of patients with 
early-stage disease, such as Masaoka stage I tumors, have excel-
lent prognosis, even with surgical excision alone.8–10 Initial com-
plete resection is one of the most powerful prognostic indicators 
of improved outcome,7,11,12 but is obviously related to tumor stage. 
Patients with advanced disease whose tumors cannot be com-
pletely resected have a lower cure rate and poor prognosis.13–15
TETs are known to be sensitive to chemotherapy (CTx), 
and the most active single agents, include cisplatin, ifosfamide, 
and doxorubicin.4,16 Although single agents are active against 
thymic tumors, combination CTx has generally led to a better 
response rate (RR)17–21 and is the basis for most current regi-
mens. The efficacy of chemotherapy, based on tumor shrink-
age and palliation of symptoms, has primarily been reported 
in patients with inoperable advanced disease.17,18,22–24 Recently, 
the incorporation of induction CTx into a multidisciplinary 
approach for the treatment of unresectable thymic tumors has 
been validated, and has shown that CTx potentially converts 
patients with inoperable disease into surgical candidates, and 
contributes to improved outcome.15,25–28 Most of these proto-
cols include anthracycline and cisplatin in the CTx regimen.
Although cisplatin/anthracycline-based CTx regimens 
produce a RR of 50% to 100% in CTx-naive patients,15,18,19,23,25–28 
anthracycline has the potential limitation of cardiotoxicity in 
a substantial proportion of patients, and some TET patients 
have pericardial involvement at the time of CTx. To date, 
there have been few reports of regimens incorporating newer 
chemotherapeutic agents, such as taxane, irinotecan, or 
gemcitabine in the treatment of TETs. Given that cisplatin 
is the most active single agent in TETs, combination CTx 
incorporating a drug that exhibits synergistic activity with 
cisplatin may be considered. Docetaxel, a third-generation 
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CTx agent, has a dramatic effect on epithelial tumors,29 and 
exhibits no cross-resistance with cisplatin, and no overlapping 
toxicities.30 In addition, in vitro data showing a synergistic effect 
between taxanes and platinums led to studies combining the two 
in patients with non–small-cell lung cancer.31,32 Recently, a few 
anecdotal studies have reported a substantial treatment response 
to paclitaxel and docetaxel monotherapy in TET patients.33,34
Here, we report the results of a prospective phase II 
study of neoadjuvant CTx using docetaxel/cisplatin to improve 
tumor resectability in patients with locally advanced TETs.
PATIENTS ANd METhodS
Study design
This was a single-center, open-label, phase II, nonran-
domized study (ClinicalTrials.gov identifier NCT01312324). 
Patient recruitment occurred between March 2007 and July 
2011. This study was approved by the Institutional Review 
Board of our institution, and written informed consent was 
obtained from all patients as per the Declaration of Helsinki. 
This study was sponsored by Sanofi Aventis; docetaxel was 
not reimbursed by insurance and the company provided a free 
supply of the medication.
Patient Eligibility
Patients with histologically proven, Masaoka stage III/
IV TETs at presentation were eligible for this prospective study. 
Before treatment, thoracic surgeons determined disease resect-
ability, and patients with inoperable disease were considered 
candidates for participation. All patients had tumors with definite 
radiologic invasion into pericardium/lung or great vessels, and had 
unidimensionally measurable lesion(s) by Response Evaluation 
Criteria In Solid Tumors criteria. Additional requirements were 
an age 15 years or more, Eastern Cooperative Oncology Group 
performance status of 0 to 2, absolute neutrophil count more than 
1000/μL, platelet count more than 50,000/μL, serum creatinine 
less than or equal to 1.5 × the upper limit of normal (UNL) or 
creatinine clearance more than or equal to 50ml/min, total biliru-
bin less than 2 × UNL, and aspartate transaminase/alanine ami-
notransferase less than 3 × UNL. Patients must not have received 
prior CTx, radiotherapy (RTx), or any investigational therapy for 
TET, and could not be pregnant. Patients with prior malignancy 
(except for adequately-treated basal cell or squamous cell skin 
cancer or in situ cervical cancer) within 5 years of the study were 
excluded from participation. In addition, patients presenting with 
any of the following concomitant acute or chronic medical ill-
ness conditions were not eligible: myocardial infarction; severe 
or unstable angina; congestive heart failure and cerebrovascu-
lar accident in the 1 year before starting CTx; ongoing cardiac 
dysrhythmias of National Cancer Institute common terminology 
criteria for adverse events grade 2 or more; uncontrolled atrial 
fibrillation of any grade; uncontrolled hypertension; uncontrolled 
diabetes mellitus.
Study Treatment
The treatment plan for all patients was three cycles of neo-
adjuvant CTx with docetaxel and cisplatin. The treatment regi-
men consisted of cisplatin 75 mg/m2 administered by infusion 
over 1 hour on day 1 and docetaxel 75 mg/m2 given intrave-
nously over 1 hour on day 1, with the infusion of docetaxel 
scheduled to commence after administration of cisplatin. CTx 
was repeated at 3-week intervals. Dexamethasone (8 mg) was 
administered orally or intravenously as a pretreatment medica-
tion to avoid acute allergic reactions. As an antiemetic protocol, 
intravenous infusion of serotonin antagonists was administered 
before docetaxel infusion, and oral dexamethasone was admin-
istered until day 5 of each CTx cycle. After induction CTx, 
clinical response was assessed within 3 to 4 weeks after the last 
CTx cycle, and subsequent surgical resection was performed, if 
appropriate. After surgery, patients with incomplete resection, 
positive resection margin, or World Health Organization type 
B2-C disease received RTx within 3 to 6 weeks of surgery. If 
radiation was thought to be potentially harmful because of a 
broad radiation field, adjuvant CTx was given instead of radia-
tion. In cases of World Health Organization type C disease, 
adjuvant CTx could be added before or after RTx, according to 
the medical oncologist’s discretion.
End points and definitions
The primary endpoint of this study was the rate of complete 
resection, defined as no microscopic residual tumor. Incomplete 
resection was defined as documented macroscopic or microscopic 
residual tumor. Secondary endpoints included RR, overall sur-
vival (OS), progression-free survival (PFS), and safety. Response 
to CTx was assessed by Response Evaluation Criteria In Solid 
Tumors version 1.1, OS was measured from initiation of treatment 
to last follow-up or death from any cause, and PFS was defined as 
time from initiation of treatment until documented progression or 
death. Toxicity during treatment was graded according to National 
Cancer Institute common toxicity criteria, version 3.0.
Statistical design
The exact binominal probability distribution approach as 
published in Gehan/Simon’s two-stage design was used. At α = 
0.05 and β = 0.2, a null-hypothesized complete resection rate of 
50% and expected complete resection rate of 75% were assumed. 
Considering a dropout rate of 10%, a total number of 27 patients 
were required. We planned to perform an interim analysis when 
the first 10 assessable patients were recruited, and if more than 
six responders are observed, at least 14 additional patients would 
have to be recruited, otherwise, the study would be terminated. 
Enrollment into the screening phase of the study was stopped 
when the anticipated number of subjects were attained.
The rate of complete resection, RR, and the frequency 
of toxicities were demonstrated using descriptive statistics. For 
calculating and comparing OS and PFS, the Kaplan–Meier method 
was used, followed by the Log-rank test. Statistical analysis was 
performed using the Statistical package for the Social Sciences 
(SPSS) version 17.0 (SPSS Inc., Chicago, Illinois).
RESULTS
Patient Characteristics
A total of 27 TET patients were consecutively entered 
into the trial and treated with neoadjuvant docetaxel/cisplatin. 
Table 1 shows the baseline characteristics of these patients. 
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The median age was 54 years (range, 15–68 years), and 59.3% 
were men. The distribution of patients, according to Masaoka 
stage at presentation, was as follows: stage III (n = 8; 29.6%), 
IVA (n = 17; 63.0%), and IVB (n = 2; 7.4%). Histologic 
type was nine thymomas (33.3%) and 18 thymic carcinomas 
(66.7%), which included one thymic carcinoid and one large-
cell neuroendocrine carcinoma; although thymic carcinoid 
and large-cell neuroendocrine carcinoma can be placed in a 
separate category of neuroendocrine tumors of the thymus, in 
general, they are classified as a type of thymic carcinoma.1,35
disease Response to Induction CTx and  
Toxicities
All patients completed the planned induction CTx. After 
completion of CTx, 17 (63.0%) achieved partial response and 
10 (37.0%) had stable disease (Table 2). Chemotherapeutic 
agents were administrated with dose modification in seven 
patients because of toxicity. Table 3 demonstrates the toxicities 
TABLE 1.  Patient Characteristics
Baseline Characteristics n (%)
Age, median (yr, range) 54 (15–68)
Sex
 Male/female 16 (59.3%)/11 (40.7%)
Masaoka stage
 III 8 (29.6%)
 IVA 17 (63.0%)
 IVB 2 (7.4%)
WHO histologic type
 B1 + B2 1 (3.7%)
 B2 4 (14.8%)
 B2 + B3 1 (3.7%)
 B3 3 (11.1%)
 C 18 (66.7%)
WHO. World Health Organization.
TABLE 2.  Clinical Information of Patients Treated with Neoadjuvant Chemotherapy
Patient No. Histologic Type Masaoka Stage Radiologic Response Surgerya Complete Resection
1 Squamous carcinoma III PR No (inoperable) —
2 Squamous carcinoma III SD Yes3 No (R2)
3 Thymoma, B1 + B2 IVA PR Yes1,4,6 R0
4 Thymoma, B2 + B3 IVA PR Yes1,5 R0
5 Squamous carcinoma IVA PR No (patient’s refusal) —
6 Squamous carcinoma IVA PR No (inoperable) —
7 Squamous carcinoma IVA PR Yes2,4,6 R0
8 Thymoma, B2 IVA SD Yes3–6 R0
9 Thymoma, B2 IVA PR Yes3–5 R0
10 Squamous carcinoma IVA SD Yes3,5,6 R0
11 Squamous carcinoma IVA PR Yes3,5 No (R1)
12 Squamous carcinoma IVA PR No (inoperable) —
13 Thymoma, B3 IVA PR Yes1,5,6 R0
14 Adenocarcinoma III PR No (follow-up loss) —
15 Large-cell neuroendocrine carcinoma IVA SD Yes3,5,6 R0
16 Squamous carcinoma III PR Yes3,6 R0
17 Atypical carcinoid III SD Yes3,5,6 No (R1)
18 Squamous carcinoma IVA SD Yes1,5,6 R0
19 Squamous carcinoma IVB PR Yes3,5,6 R0
20 Squamous carcinoma IVA PR Yes3,4 No (R2)
21 Thymoma, B3 IVA SD No (inoperable) —
22 Squamous carcinoma III SD Yes6 R0
23 Thymoma, B2 IVA SD Yes4,5 R0
24 Thymoma, B1 or B2 IVA PR No (inoperable) —
25 Thymoma, B3 III SD Yes3 R0
26 Thymic carcinoma III PR No (surgeon’s decision; 
no need for operation)
—
27 Squamous carcinoma IVB PR Yes3,5 R0
aInformation on operation other than total thymectomy is addressed by suffix; 1 = extrapleuropneumonectomy, 2 = pneumonectomy, 3 = partial resection of lung, 4 = partial 
resection of pleural mass, 5 = partial resection of pericardium, and 6 = partial resection of vessels.
SD, stable disease; PR, partial response, RTx, radiotherapy, CTx, chemotherapy.
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observed during induction CTx. Major side effects of CTx 
included grade 3 anorexia (n = 1), nausea (n = 2), diarrhea 
(n = 3), and alopecia (n = 1). Major hematologic toxicities 
involved grade 3 leukopenia (n = 2), anemia (n = 1), thrombo-
cytopenia (n = 1), and grades 3 to 4 neutropenia (n = 8).
Surgery after Induction CTx and 
Postoperative Treatment
Nineteen patients (70.4%) underwent surgical resec-
tion and eight patients did not for the following reasons: sur-
geon’s decision of inoperable disease (n = 5); patients’ refusal 
(n = 2, including 1 patient who was lost to follow-up); radia-
tion therapy alone after docetaxel/cisplatin was considered 
sufficient to eradicate the disease (n = 1). Of 19 patients under-
going surgical resection, 15 had complete resection, and four 
had incomplete resection. All four patients with incomplete 
resection had thymic carcinoma. Among the patients with 
incomplete resection, two had macroscopic residual tumor at 
operation field (R2 resection) and the remaining two showed 
microscopically positive resection margin (R1 resection). All 
seven patients who underwent surgery for thymoma achieved 
complete resection. After completion of surgical resection, 
subsequent therapy was performed as follows: radiotherapy 
(RTx; n = 8), chemotherapy (CTx; n = 7), radiotherapy with 
chemotherapy (RTx + CTx; n = 2), and observation (n = 2). 
Among the eight patients not undergoing surgery, three 
received definitive RT, four had palliative CTx, and one was 
lost to follow-up.
overall Survival and disease Free Survival
With a median follow-up of 42.6 months, 4-year OS and 
PFS in all patients was 79.4 and 40.6%, respectively. When 
comparing OS and PFS according to achievement of complete 
resection after neoadjuvant docetaxel/cisplatin, patients with 
complete resection showed 4-year OS of 92.9% and 4-year 
PFS of 50.3%, compared with 62.2 and 31.2%, respectively, in 
patients who did not achieve complete resection (Fig. 1; OS; 
p = 0.19; Fig. 2, PFS, p = 0.41).
dISCUSSIoN
TETs are a heterogeneous group of diseases, with a 
wide spectrum of morphologic appearance.3,4,36 Thymoma 
and thymic carcinoma are the most frequent histologic sub-
types, but thymic carcinoma is a distinct entity based on its 
obvious cytologic atypia.12 Compared with thymoma, thymic 
TABLE 3.  Toxicities
Grade 
1
Grade 
2
Grade 
3
Grade 
4
% of Patients 
with Toxicity  
≥ Grade 3
Anorexia 5 3 1 0 3.7%
Nausea 5 1 2 0 7.4%
Vomiting 1 1 0 0 0%
Diarrhea 2 2 3 0 11.1%
Stomatitis 2 3 0 0 0%
Mucositis 2 1 0 0 0%
Fatigue 3 0 0 0 0%
Myalgia 4 2 0 0 0%
Alopecia 8 8 1 0 3.7%
Fever 2 0 0 0 0%
Peripheral neuropathy 4 1 0 0 0%
Ototoxicity 1 0 0 0 0%
Leukopenia 0 7 2 0 7.4%
Neutropenia 1 4 5 3 29.6%
Anemia 8 9 1 0 3.7%
Thrombocytopenia 3 0 1 0 3.7%
FIGURE 1 .  Overall survival according to complete 
resection after induction therapy.
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carcinoma shows more invasive and malignant behavior, and 
previous reports have demonstrated worse survival.12,37 Tumor 
stage and completeness of resection are also important factors 
for prognosis. OS rate is closely related to stage,1,10,13,38–41 and 
complete resection of thymic tumor significantly increases 
the survival rate, even for patients with advanced stage.4,9,13,42 
Among various clinical factors, complete resection is one of 
the most important prognostic factors,10 therefore, all patients 
with thymic tumors should be evaluated by an expert thoracic 
surgeon for their resectability, and every effort should be 
made to achieve resectability in patients with initially inoper-
able disease.
Thymic tumors are sensitive to CTx. A variety of CTx 
agents and combination regimens have been reported, with an 
objective RR between 10% to 100%, depending on the study.1 
CTx regimens used in thymic tumors have been primarily 
cisplatin-based, and anthracycline is the most often used agent 
in conjunction with cisplatin,18,22,23,43 although etoposide and 
ifosfamide have been variably incorporated into a cisplatin-
based regimen.43,44 So far, the best results in phase II studies 
of CTx for inoperable thymic tumors have been obtained 
with ADOC regimen (doxorubicin, cisplatin, vincristin, 
cyclophosphamide), with a 92% RR, including a 43% 
complete response.23 However, direct comparison between 
regimens is not easy1 because of the small size of the series 
as a result of the rarity of the disease and the heterogeneous 
distribution of patients with thymoma or thymic carcinoma in 
each series. Consequently, although it is clear that a variety 
of chemotherapy regimens are active against thymic tumors, 
we cannot definitively say which regimens offer a significant 
advantage for this type of tumor.
The rationale for induction CTx in patients with locally 
advanced thymic tumor is to facilitate complete surgical 
resection, resulting in a higher cure rate. Successful treatment 
of primary disease and metastatic regional nodes is crucial, 
and we conceived the idea that incorporation of docetaxel 
into a cisplatin regimen may be efficacious in thymic tumors. 
This was based on in vitro data showing collateral sensitivity 
and a lack of cross-resistance between taxane and platinums30 
and their successful use in other epithelial tumors, such as 
non–small-cell lung cancer. In addition, several reports have 
reported antithymoma activity of taxane when used in mono-
therapy or combination therapy.33,34,45
In this study, we report the results of a prospective 
phase II study of neoadjuvant CTx using docetaxel/cisplatin 
in patients with locally advanced TETs. With intent-to-
treat analysis, 15 of 27 patients (55.6%) achieved complete 
resection after induction CTx. Of 26 patients whose 
resectability could be assessed after neoadjuvant CTx by an 
expert thoracic surgeon (1 of 27 patients was lost to follow-up 
after CTx), initially inoperable lesions were converted to 
resectable diseases in 21 cases (21 of 26; 80.8%). Of these 
21 cases, two patients did not undergo surgical resection: one 
patient decided not to undergo surgery because RTx alone 
was considered sufficient to eradicate the residual lesion 
(although this case broke the protocol), and one patient 
refused surgery because of fear of pleuropneumonectomy. 
Of 19 patients who underwent surgery, 15 patients achieved 
R0 resection (78.9%), two achieved R1 resection (10.5%), 
and the remaining two had R2 resection (10.5%). Table 4 
summarizes the results of previous reports of induction CTx 
approaches in locally advanced thymic tumors. However, 
although this gives a rough indication of differences in 
clinical outcome from each regimen, given the heterogeneous 
distribution of patients regarding tumor stage, histology, and 
postoperative treatment, direct comparison between regimens 
is quite limited, and deemed to be invalid. The complete 
resection rate with our regimen was comparable with that of 
other studies, but the radiologic RR was relatively low, and 
no patient achieved complete response. However, it should be 
FIGURE 2.  Progression-free survival according to 
complete resection after induction therapy.
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TABLE 4.  Induction Chemotherapy Approaches in Locally Advanced Thymic Tumors
Chemotherapy 
Regimen (Author, yr) Stage Histology (No. of Patients)
Response  
Ratea  
(CR rate)
No. of Patients with 
Complete Resection/No. 
of Surgical Resection 
Patients (%)
Postoperative  
Treatment OS PFS
Cisplatin
III
Thymoma (4) Thymic  
carcinoma (3)
100% (57%) 4/7 (57.1%) RTx 80% 2 yr 80% 2 yr
Epirubicin
Etoposide
(Maccjiarini P, 1991)
Cisplatin
III IV Thymoma (16) 100% (43%) 11/16 (68.8%) CTx or RTx 70% 3 yr NA
Doxorubicin
Vincristine
Cyclophosphamide
(Rea F, 1993)
Cisplatin
III IV Thymoma (22) 77% (14%) 16/21 (76%) RTx and CTx
95% 5 yr  
79% 7-yr
77% 5 yr  
77% 7-yr
Doxorubicin
Cyclophosphamide
Prednisone
(Shin DM, 1998)
Cisplatin
III
Thymoma (34) (11)b Thymic 
carcinoma (11) (4)b
66.6% (13%)c 13/15 (87%)c RTx and CTx 78% 10 yr 53% 10 yr
Epirubicin
Etoposide
or
Cisplatin
Doxorubicin
Cyclophosphamide
(Loehrer PJ, 1994)
Cisplatin
III IV
Thymoma (9) Thymic 
 carcinoma (18)
63% (0%) 15/19 (78.9%)
RTx or CTx or 
RTx + CTx
93% 4 yr 50% 4 yr
Docetaxel (current study)
*Radiologic response, Complete response.
bNot all patients included in this study received induction therapy. bIndicates the number of patients who received preoperative chemotherapy.
cIndicates the proportion of patients among those who received induction chemotherapy only.
RTx, radiotherapy; CTx, chemotherapy; CR, complete response.
FIGURE 3.  Overall survival according to histologic 
type.
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noted that a substantial number of patients with unfavorable 
features were included in the current study; there were more 
patients with stage IV lesions (19 of 27; 70.4%) than stage 
III tumors (8 of 27; 29.6%), and a large proportion of this 
cohort were patients with thymic carcinoma rather than 
thymoma (18 of 27; 66.7%). When comparing complete 
resection rates according to histology, the seven thymoma 
patients who underwent surgery obtained complete resection, 
whereas, four of 12 patients with thymic carcinoma had 
residual disease. In addition, survival curves according to 
pathologic subtypes showed that all patients with thymoma 
were alive at least until the last follow-up date, in contrast to 
patients with thymic carcinoma (Fig. 3), further emphasizing 
the adverse clinical features of thymic carcinoma. Although 
a relatively short follow-up period (42.6 months) can be a 
major limitation of this study, the overall 4-year survival rate 
of 79.4%, despite the substantial proportion of patients with 
thymic carcinoma, was not disappointing.
In summary, the results of this current prospective phase 
II study of neoadjuvant chemotherapy using docetaxel/cispla-
tin suggest that this regimen is feasible and can potentially 
improve tumor resectability in patients with locally advanced 
TETs.
We certify that there is no conflict of interest with any 
financial organization regarding the material discussed in the 
article.
This study was sponsored by Sanofi Aventis; the com-
pany provided a free supply of the docetaxel.
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